Background: This study assesses the reliability and validity of the Dutch version of a disease-specific measure of health-related quality of life (HRQOL) for adolescents and adults with CF (CFQ-14q). The 47-item CFQ-14q covers nine domains, three symptom scales and one health perception scale. Methods: To assess psychometric characteristics of the CFQ-14q, cross-sectional (homogeneity, discriminative and construct validity) and test-retest designs were used. Eighty-four adolescents and adults with CF (mean age: 21.4 years, range 14.0-46.5 years) and a wide range of lung function (mean FEV : 59,9% predicted, range 15-1 121%) completed the questionnaire during a routine visit. Results: Internal consistency was acceptable for most domains of the CFQ-14q (as0.43-0.92) and test-retest reliability was high for all domain scores (0.72-0.98). Several domains of the CFQ14q were able to differentiate between individuals with varying disease severity and between nourished and malnourished patients. Construct validity of the questionnaire was fair, with moderate to strong correlation between physically orientated domains and pulmonary function (r s0.36-0.62). Conclusion: The results demonstrate that the CFQ-14q questionnaire is a s well-validated measure of HRQOL assessment in adolescents and adults with CF.
Introduction
Advances in therapy and treatment of cystic fibrosis (CF) have led to improved patient survival into adulthood w1x. However, therapy and treatment of CF, coupled with the progressive nature of the disease, which can require hospitalization, makes management of CF timeconsuming and difficult w1,2x. Traditional clinical measures are important but they do not capture the broader impact of the disease w3-5x. The measurement of healthrelated quality of life (HRQOL) in CF provides additional information about the impact of the disease on physical, social and psychological functioning w2,5,6x. Studies on HRQOL in patients with CF have typically used generic or specific respiratory questionnaires which were not specifically developed for CF w7-12x. Generic health measures allow for comparisons between a variety of diseases, but are not sensitive for specific problems associated with CF w6x and may not be sufficiently responsive to the effects of clinical interventions. Recently, a reliable and valid CF-specific health-related measure was developed and validated in France, the Cystic Fibrosis Questionnaire (CFQ) w13x. In addition, the CFQ has been validated in Germany w14x and is presently being validated in the United States and Spain. The CFQ consists of three quality of life measures: an adolescentyadult version (14 years of age or older), a child version (6-13 years of age) and a parent version (used in conjunction with the child measure). The advantage of the CFQ is that it takes into account differences in developmental stages and makes it possible to monitor the health status and quality of life in CF patients from the age of 6 years throughout adulthood w6,15x. This allows health care professionals to analyze long-term outcome and efficacy of early intervention.
Cross-cultural validation of an existing measure has the advantage of avoiding the initial stages of development of a new questionnaire, which is a long process w16,17x. Furthermore, translation into different languages makes it possible to use the CFQ questionnaires in comparative international multi-center studies w16x.
The aims of the present study were: (1) to develop a conceptually equivalent Dutch version of the CFQ for adolescents and adults with CF and (2) to evaluate the following characteristics: homogeneity, reproducibility (10-14 days test-retest reliability), discriminative and construct validity.
The Dutch CFQ for children with CF and their parents is presently being validated.
Methods

Patients and procedure
Eighty-four patients were recruited from the children and adult CF-Center of the University Medical Center Utrecht. All patients were approached during routine visits between 2001 and 2002 and asked for consent to complete the CFQ. Patients who had problems understanding the Dutch language were excluded from the study. In a subset of clinically stable patients, as determined by a pulmonologist, the questionnaire was administered twice within 10-14 days. The study was approved by the institutional Medical Ethics Committee.
Translation
Backward and forward translations were completed. The French CFQ was translated into Dutch and a second independent translator made a backward translation into French. A third expert compared the original French list to the backward translated French list. Discussions were held between the translators to resolve semantic and conceptual discrepancies and to develop a consensus forward translation.
Cystic fibrosis questionnaire
The CFQ for adolescents and adults (CFQ-14q) consists of 47 items divided into nine domains: physical functioning (8 items), energy and well-being (4), emotional state (5), social limitations (4), role limitations (2), body image (3), eating disturbances (2), treatment burden (2), and embarrassment (3). Three symptom scales are included, respiratory (7), digestive (2), and weight (1), and overall health perception (4). Items require either a frequency response on a 4-point scale ('all the time' to 'never'), a difficulty rating on a 4-point scale ('a lot of difficulty' to 'no difficulty'), a true-false rating on a 4-point scale, or the selection of a statement that describes the patient (on a 3-or 4-point scale) w6x. Completing the questionnaire took approximately 15 min.Scores are standardized by adding the ratings of all items within a domain to facilitate comparison of scores across domains. The scores range from 0 to 100 with higher scores corresponding to higher quality of life. Scores for each domain are calculated if at least two-thirds of the items are completed. There is no total score.
Appendix A outlines the distribution of the questions by domain for CFQ-14q.
Homogeneity
Internal consistency of each domain was assessed using Cronbach alpha coefficients (i.e. the strength of the associations between items and their respective domains). Generally the internal reliability is acceptable with a Cronbach alpha coefficient of 0.7 or above w18x. However, slightly lower coefficients (0.6 or higher) are acceptable for newly developed scales w19x. Furthermore, item to domain correlations were calculated. These correlations assess whether items are more strongly associated with their hypothesized vs. competing scale. Psychometric guidelines suggest that item to domain correlations should be 0.40 or greater w19x.
Reproducibility
Test-retest reliability measures the stability of the scores on the CFQ questionnaires over time. Twentyone patients with a stable clinical condition (i.e. no need for oral or intravenous antibiotic treatment in 3 months prior to testing) completed the CFQ 10-14 days apart. This period is long enough not to introduce memory as a confounding factor while being short enough to prevent deterioration in disease status w20x.
Discriminative and construct validity
To assess whether the measure could discriminate between patients with varying levels of disease severity, patients were categorized according to their level of pulmonary impairment: mildly impaired group (FEV1G71%pred), moderately impaired group (FEV1 41-70%pred) and severely impaired group (FEV1F40%pred) w20x. In addition, patients were categorized according to their nutritional status: nourished group (BMI G19) and malnourished group (BMI -19). Since disease severity is related to older age comparisons were made between age groups: adolescents (14-17 years), young adults (18-25 years) and adults (26 years of age and older). Comparisons were also made between males and females.
Construct validity was assessed by correlating CFQ scores with pulmonary functioning.
Pulmonary function
Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) were obtained from maximal expiratory flow-volume curves (Masterscreen; Jaeger, Wuerzburg, Germany). Values are expressed as the percent of predicted values w21,22x.
Statistical analyses
The Statistical Package for the Social Sciences (SPSS for Windows version 10.1) was used for data management and analyses. The internal consistency reliability was evaluated using Cronbach's a. Spearman (rs) correlation coefficients were used to describe relationships between outcome measures. Correlations were interpreted as described by Guyatt and colleagues: less than 0.2 as very weak, from 0.2 to 0.35 as weak, from 0.35 to 0.5 as moderate, and 0.5 or greater as strong w23x. Intraclass correlation coefficients were used to estimate the reproducibility (test-retest reliability) w24x. Domain comparisons between groups were made using t-tests for unrelated samples and one-way analysis of variance (ANOVA). Post hoc testing was done with Tukey's honest significant difference, which corrects for multiple comparisons. Effect sizes (ES, i.e. the ratio of difference in mean scores to the pooled baseline standard deviation w25x were calculated to assess the relative magnitude of observed differences. ES is interpreted using criteria described by Cohen: 0.2 represents a small relevant difference; 0.5 a moderate difference and differences of 0.8 or higher are interpreted as a large difference w26x. Differences were considered significant if P-0.05 (twotailed). Data are presented as mean "S.D. unless otherwise indicated.
Results
Eighty-four patients with CF (mean age: 21.4 years, range 14.0-46.5 years) who had moderate to severe airway obstruction (mean FEV1: 58.5%, range 15-121%; mean FVC: 74.1%, range 26-121%) completed the CFQ-14q. Table 1 shows mean values of the different domains. The lowest scores on the CFQ-14q were found for vitality and respiratory symptoms, while the highest scores were found for digestion and embarrassment.
Internal consistency
The internal consistency reliability levels (Cronbach alpha) for the domains of the CFQ-14q are shown in Table 1 . Most domains had an acceptable Cronbach alpha coefficient (0.60 or above). The exceptions to this were body image, treatment burden and embarrassment. Overall, items in the CFQ-14q loaded conceptually on their respective domains with all of the loadings above 0.40.
Reproducibility
Twenty-one patients (22.8"8.9 years; range 13.9-36.4 years) with moderate pulmonary dysfunction (FEV1 62.1%"20.0%; range 29.2-87.0%) agreed to participate in the test-retest reliability phase. The intraclass correlation coefficients were high for all domains, ranging from 0.72 to 0.98 (Table 1) . This means that the domain scores of the CFQ-14q are highly reproducible.
Discriminative and construct validity
To assess whether the measure could differentiate between patients with varying degrees of disease severity, patients were categorized according to the level of pulmonary impairment ( Table 2) . Three groups were formed: mildly impaired group (Ns28, FEV1 89.1%"14.0%), moderately impaired group (Ns36, FEV1 56.0%"8.6%) and severely impaired group (Ns 20, FEV1 26.4%"7.1%). ANOVA tests indicated significant main effects for physical functioning (Fs27.34, P-0.001), body image (Fs13.43, P-0.001), eat disturbances (Fs5.17, P-0.01), respiratory symptoms (Fs5.78, P-0.01), health problems (Fs4.16, P-0.015) and weight (Fs5.57, P-0.01). Table 3 shows The scores range from 0 to 100 with higher scores corresponding to higher quality of life. Comparisons were made between adolescents (Ns 35; 15.4"1.1 years), young adults (Ns31; 20.5"1.4 years) and adults (Ns18; 34.5"6.3 years). ANOVA tests indicated significant main effects for physical functioning (Fs13.56, P-0.001), vitality (Fs4.44, P-0.05), body image (Fs6.29, P-0.01), treatment burden (Fs3.58, P-0.05), respiratory symptoms (Fs 9.87, P-0.01), health perceptions (Fs10.17, P-0.01). Post hoc analyses revealed the following differences between age groups: (1) adolescents reported higher quality of life than young adults for the body image domain; (2) adolescents reported higher quality of life than adults for the domains of physical functioning, vitality, body image, treatment burden, respiratory symptoms, digestion and health perception; (3) young adults reported higher quality of life than adults for the domains of physical functioning, vitality, respiratory symptoms and health perception.
Comparisons between male (Ns44) and female (Ns 40) patients demonstrated that males had higher scores for the emotional functioning domain (80.9"12.2 vs. 74.2"18.1, P-0.05) and lower scores for the body image domain (62.9"24.3 vs. 75.0"15.0, P-0.01). Table 5 shows weak to moderate correlations for pulmonary function with treatment burden, health perceptions, weight, eating disturbances, respiratory symptoms, and strong correlations with physical functioning, and body image. The results indicated that patients with worse pulmonary function reported poorer quality of life on these domains.
Discussion
This study assesses the reliability and validity of the Dutch version of a disease-specific measure of HRQOL for adolescents and adults with CF (CFQ-14q). The conceptual model of the CFQ was confirmed and the internal consistency was acceptable for most domains. Strong test-retest reliability was obtained and discriminative validity with pulmonary function, nutritional status and age was demonstrated.
The homogeneity and the internal consistency reliability estimates of the CFQ-14q were adequate. However, three domains showed a low Cronbach alpha coefficient. Internal consistency coefficients of the treatment burden domain have found to be even lower in previous studies w27x. One possible reason for this is that early detection of CF leads the initiation of treatment regimens at a very young age. Patients may slowly accommodate to deterioration in their health status and a concomitant increase in the treatment regimen. Therefore, they may not perceive this as limiting their daily functioning. Internal consistency on the body image domain was also poor. The low alpha coefficient was, in part, caused by a gender effect. The Cronbach alpha for males and females was 0.56 and 0.10, respectively. However, deleting gender-based items or scales could lead to losing important information related to males and females with CF. For example, there is a significant gender difference in morbidity and mortality among males and females with CF which may be better understood in relation to their HRQOL scores w28x. Recently, revisions were made in the body image, treatment burden and Embarrassment domains to improve validity. These items will be tested in subsequent studies with the CFQ.
Currently, there is only one other validated CFspecific HRQOL measure for adolescents and adults (CFQoL) w20x. The authors reported high Cronbach alpha coefficients on all domains. However, this measure does not have a version for children with CF. After evaluation of the Dutch child version, which is presently underway, the CFQ questionnaires make it possible to follow individual patients throughout their life span and to capture the impact of the disease on the patient's ability to cope with various aspects of the illness. Furthermore, there was no effort to counterbalance positively and negatively worded items on the CFQoL, which can skew the wording of the items in a negative direction ('CF makes it difficult for me to«').
The analysis of test-retest reliability showed high intraclass correlations, indicating that the assessment of HRQOL is stable over a 10-14 day period. However, the patients who participated in the test-retest reliability phase were only moderately impaired which might have effected the results. Further testing of the test-retest reliability of the CFQ in patients with a greater variety of respiratory impairment is, therefore indicated.
The CFQ-14q questionnaire seems applicable to a broad population of patients with CF since differences in CFQ scores were not only found for all severity groups (as measured by FEV1) but also for nourished and malnourished patients. It is important to note that the discriminative validity with respect to pulmonary function only showed significant differences between severity groups for six domains. However, the sample size for this study was relatively small and in order to account for the effect of sample size effect sizes were calculated. Small effect sizes (-0.5) indicate that statistically significant outcome might be a function of sample size. Stronger evidence of discriminative validity might have been found in the vitality, social functioning, emotional state and role limitations domains with a larger sample size. However, CFQ scores on these domains were clearly reduced. Although respiratory involvement is of major importance because pulminary disease is primarly responsible for morbidity and mortality in patients with CF w1x, pulmonary function measurements are possibly not sensitive enough to detect differences on these domains between subgroups patients with this multi-systemic disease.
Important differences were also found age and sex. These findings converge with the results of other studies, showing that gender differences exist in morbidity and mortality with CF w28,29x. Clinicians should beware of the fact that thinness and low body weight are perceived by women as less of a problem than males w6x, although this condition is unfavarouble for their health w30-32x.
Some issues in the present study need further comment. Although the construct validity of the CFQ-14q with pulmonary function is good, assessment of its relationship to generic health status and psychological well-being should be conducted. Data are also needed on the responsiveness of the CFQ-14q, which measures whether a questionnaire is able to detect changes brought about by an intervention. However, a prerequisite of sensitivity testing is the establishment of the reliability and stability of the measure, which in this study, appears to be very good. Evaluation of the child and parent versions of the CFQ is presently underway.
Generic HRQOL and respiratory-specific questionnaires are unlikely to reflect adequately the symptoms and areas of functioning that are relevant for majority of patients with CF w5,33x. Incorporating disease-specific HRQOL measurements with the CFQ-14q questionnaire in the care of patients may improve our understanding of the impact of CF on the lives of these patients in several ways. Firstly, it may be helpful in detecting transient changes in health status caused by worsening in pulmonary function or pulmonary exacerbations that are both associated with deterioration in psychosocial and physical functioning. Secondly, our understanding of the basic pathophysiological mechanisms and significant improvements in diagnosis and treatment have increased. These developments improved prognosis and median survival. Recent estimates have projected a median survival of 40 years for children born in 1990 who are receiving current standard therapy for CF w34,35x. However, the quality of this improved survival has not been assessed. The CFQ-14q can be used to describe longitudinal changes as a function of deterioration in disease status w20x. Changes on a psychosocial level that take place over time may thereby supplement traditional physiological measurements like pulmonary function. Thirdly, the CFQ-14q may be useful in understanding more clearly how clinical trials or specific interventions (e.g. aerosol therapy, tube feeding) may impact patient perceptions of HRQOL. Fourthly, the CFQ-14q may improve communication between clinicians and patients by facilitating discussion on issues that are of importance to patients. This enables clinicians to focus more attention on patient's individual perceptions of illness and prioritize problems by their importance to patients and thereby informing medical decision-making. Moreover, patient's perceptions of improved functioning that are not reflected in conventional medical outcomes may be an important factor in promoting adherence to time-consuming and tedious therapy w5x.
We conclude that the results show adequate validity and reliability of the CFQ-14q questionnaire. This measure holds promise for assessing HRQOL in multicenter international studies. 
Appendix A: List of items of the Dutch CFQ-14H
